Navigation Links
Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of premium-priced biologics will drive the systemic lupus erythematosus drug market to more than quadruple from approximately $420 million in 2008 to nearly $2 billion in 2018.

The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the primary drivers of market growth will be the entry and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, Biogen Idec/Roche's ocrelizumab, and Immunomedics/UCB's epratuzumab. In 2018, these three agents, combined with the continued uptake of rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera), will account for more than 80 percent of sales in the systemic lupus erythematosus drug market. In 2008, the market was characterized by extensive use of generics and the majority of sales were driven by the off-label use of two branded agents -- Roche/Galenica's CellCept and rituximab. The off-label use of CellCept, rituximab and other therapies exemplifies the unusual dynamics of the systemic lupus erythematosus market.

"The continued uptake of rituximab, despite its failure in recent clinical trials, highlights the significant challenges associated with drug development for systemic lupus erythematosus, the high unmet need in the indication and the unusual dynamics of this market," said Decision Resources Analyst Dancella Fernandes, Ph.D. "Rituximab's contribution to growth will be greater in the near-term but, from 2013 to 2018, its sales will decline modestly as biosimilar versions of the drug emerge in Europe in 2013 and in the United States in 2015."

The report also finds that the partial replacement of current, predominantly generic, immunosuppressants by branded, premium-priced immunosuppressants will also contribute to market growth. Novartis's Myfortic and Roche/Galenica's CellCept will take market share away from GlaxoSmithKline/Prometheus's Imuran as maintenance treatments as well as Bristol-Myers Squibb's Cytoxan as induction treatments.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563        

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
2. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
3. China Biologic Products Hosts its First Forum for Strategy and Development
4. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
5. MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis.
6. CQ Forum on Biosimilar Biological Products - Wed., June 17, 2009
7. China Biologic Products Closes the $9.6 Million Private Placement
8. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
9. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
10. Results From Neurotechs NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
11. Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced ... 29, 2015 at 11:00 a.m. Israel time, at ... 98 Yigal Allon Street, 36 th Floor, Tel Aviv, ... Eric Paneth and Izhak Tamir to the Board of ... as external directors; , approval of an amendment to certain terms ...
(Date:11/24/2015)... Nov. 24, 2015  Twist Bioscience, a company ... Leproust, Ph.D., Twist Bioscience chief executive officer, will ... on December 1, 2015 at 3:10 p.m. Eastern ... City. --> --> ... Twist Bioscience is on Twitter. Sign up to ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
Breaking Biology News(10 mins):